Evaluation of intravenous clonidine as a hypotensive agent as part of balanced anaesthetic technique in functional endoscopic sinus surgery (FESS) by Meghna, S David
 
 
Evaluation of intravenous Clonidine as a hypotensive 
agent, when used as a part of balanced anaesthetic 
technique in functional endoscopic sinus surgery (FESS) 
 
 
MEGHNA S. DAVID 
 
 
 
 
 
 
 A dissertation submitted in partial fulfillment  of M D Branch(Anaesthesiology) 
Examination of the The Tamil Nadu Dr.M.G.R. Medical University, Chennai 
 
 
CERTIFICATE 
This is to certify that the  dissertation entitled “Evaluation of intravenous 
Clonidine as a hypotensive agent as part of balanced anaesthetic technique in 
Functional endoscopic  sinus  surgery (FESS)” is a  bonafide work of                       
Dr. Meghna S. David in partial fulfillment of  M D Anaesthesiology Examination of  The 
Tamil Nadu Dr.M.G.R. Medical University, Chennai, to be held in September 2010. 
 
 
Guide:  Head of Department: 
Dr. K. Subramani                                        Dr. Sarah Ninan 
Assoc. Professor                       Professor and Head 
Department of Anaesthesiology                Department of Anaesthesiology 
Christian Medical College & Hospital                    Christian Medical College & Hospital 
Vellore                                     Vellore 
 
                            
 
 
 
 
 
ACKNOWLEDGEMENT 
Towards the fulfillment of my dissertation, first and foremost,I would like to acknowledge 
God’s grace and wisdom that has guided me unceasingly. 
I express my sincere gratitude to my guide, Dr.K.Subramani, Associate Professor, 
Department of Anesthesiology for his help, able guidance and valuable suggestions. 
I would like to thank Dr. Sarah Ninan, Professor and Head, Department of 
Anaesthesiology, for her support and cooperation. 
I would like to thank Dr. Anitha Shirley, Dr. Kamal Kumar and Assistant Professors, 
Department of Anaesthesiology for their help and support in conducting the study. 
I would like to thank Mr. Jeevagan and the anaesthesia technicians for their sincere help in 
arranging the equipments and drugs required for the study. 
I am thankful to Mr.Prasanna, Department of Biostatistics, Christian Medial College & 
Hospital, Vellore for helping in the statistical analysis. 
I would like to express my gratitude to the Department of ENT 
(Units I,II.and III) ,as well as the ENT operation theatre staff for their cooperation and 
support during the course of this study. 
A word of appreciation and gratitude to all my colleagues in the Department of 
Anaesthesiology for their help and cooperation. 
I am grateful for the loving and affectionate support of my family, without which, I would 
not have been able to complete this study. 
Last but not the least, I am thankful to all the patients who participated in this 
study,without whom,this study would not have been possible. 
 
 
 
CONTENTS 
S.No. Content Page. No. 
1 INTRODUCTION 1 
2 AIMS & OBJECTIVES 3 
3 REVIEW OF LITERATURE 4 
4 METHODOLOGY 28 
5 RESULTS 34 
6 DISCUSSION 48 
7 CONCLUSIONS 52 
8 BIBLIOGRAPHY  
9 
 
APPENDICES: 
 
1. Proforma 
2. Informed consent sheet 
3. Data entry sheet 
4. Key to data entry sheet 
 
 
 
1 
 
INTRODUCTION 
Functional endoscopic sinus surgery (FESS) is a minimally invasive surgery of 
the paranasal sinuses. 
            The main aim of FESS is to restore drainage and aeration of the paranasal 
sinuses preserving the normal anatomic structures and maintaining the natural 
mucociliary clearance mechanism (1, 2). As with any other surgery, FESS can also 
lead to complications, which can be either related injury to the structures surrounding 
the paranasal sinuses or infection. These complications are rhino-oral fistulas, optic 
nerve injury, dural injury, cerebrospinal fluid (CSF) rhinorrhoea, meningitis, orbital 
plate injury, orbital cellulitis etc (3-5). 
These complications tend to occur more in the presence of excessive bleeding 
during the surgery(3), which obscures the field of operation (6).  A “bloodless field” 
would provide the surgeon with a clear field minimizing the risk of injury to the vital 
structures. This would also minimize the intraoperative blood loss as well as the 
surgical time. 
“Bloodless field” can be achieved by inducing controlled hypotension (7) with 
various agents like inhalational anaesthetic agents (8-10), beta blockers (5), 
vasodilators like nitroglycerine (GTN) and sodium nitroprusside (SNP) (5) and 
intravenous (IV) anaesthetic agent like propofol (11). When inhalational anaesthetic 
agents are used on their own, they can cause a delay in awakening, shivering etc 
during the recovery period, which is undesirable. Beta-blockers do not have analgesic 
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or sedative properties. Propofol needs a continuous infusion throughout the surgery. It 
lacks analgesic effects and is relatively expensive. 
Clonidine (an alpha 2 agonist) has been used as an antihypertensive for many 
years. Out side anaesthesia, it has been used in hypertensive crisis (12).  In addition to 
its antihypertensive effects, its sedative and analgesic properties have encouraged us to 
use it as an adjunct in anaesthetic practice. In anaesthesia, it has been used as a 
premedication to facilitate induced hypotension(13, 14), to reduce the requirement of 
intravenous & volatile anaesthetics (13, 15) , to suppress pressor response during 
intubation (16) and to induce hypotension with total intravenous anaesthesia (TIVA) 
(17). There have not been many studies (18) to delineate its hypotensive effect with 
inhalational agent together with its other effects, for example analgesia and sedation 
especially in the Asian population. 
In this study we propose to evaluate the hypotensive effect of Clonidine when 
used as a part of a balanced anaesthetic technique in patients undergoing FESS. In this 
randomized double blind placebo controlled study, fentanyl and metoprolol have been 
used as rescue drugs to achieve target blood pressure. 
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AIM AND OBJECTIVES 
PRIMARY OBJECTIVE: To evaluate the hypotensive effect of Clonidine when 
used as a part of balanced anaesthetic technique in FESS. 
SECONDARY OBJECTIVES:  
1. To assess the reduction in the requirement of metoprolol & fentanyl to achieve 
hypotension. 
2. To aim at ‘bloodless field’. 
3. To assess blood loss. 
4. To evaluate beneficial effects of Clonidine namely reduction in anaesthetic 
requirements and analgesia. 
5. Assess incidence of side effects namely excessive sedation, hypotension & 
bradycardia. 
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REVIEW OF LITERATURE 
FUNCTIONAL ENDOSCOPIC SINUS SURGERY  
             
 
Figure –1 Normal anatomy of paranasal sinus as seen on CT scan 
E - Ethmoid sinus; M - Maxillary sinus; S – Nasal septum; IT - Inferior  turbinate 
MT - Middle turbinate; U -  Uncinate Process 
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Removal of the uncinate process of the ethmoid bone allows resection of the 
anterior ethmoid air cells, with subsequent reestablishment of ventilation and drainage 
of the maxillary and frontal sinuses through their natural ostia.  Surgery is performed 
through the nostrils and therefore, there are no external incisions. 
                 
 
Figure –2 Normal anatomy versus operated side in FESS 
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FESS is the mainstay in the surgical treatment of chronic sinusitis and nasal 
polyposis. It is a relatively recent surgical procedure that uses nasal endoscopes to 
minimise cutting and  trauma to the skin (2). 
FESS was popularised following the pioneering work of Messerklinger & 
Stamberger (Graz, Australia). Rhinology & sinus surgery have undergone a 
tremendous expansion since the discourses of Messerklinger and Wigand in the late 
1970’s. Improved understanding of the anatomy and pathophysiology of chronic 
sinusitis, advances in imaging techniques and image guided surgery have allowed 
surgeons to perform more complex procedures with increased safety. 
INDICATIONS: 
The most common indications for endoscopic sinus surgery are as follows: 
 Chronic sinusitis refractory to medical treatment 
 Recurrent sinusitis 
 Nasal polyposis 
 Antrochoanal polyps 
 Sinus mucoceles 
 Excision of selected tumors 
 Closure of CSF leak. 
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 Orbital decompression (e.g. Graves ophthalmopathy) 
 Optic nerve decompression 
 Dacryocystorhinostomy (DCR) 
 Repair of choanal atresia 
 Removal of foreign body 
 Control of epistaxis 
COMPLICATIONS: 
            Extreme care is required in this surgery due the proximity of paranasal sinuses 
to the orbits, brain, internal carotid arteries and optic nerves. The complications related 
to FESS are as follows: 
1. Orbital complications: 
a. Orbital haemorrhage 
b. Abscess and  
c. Optic nerve injury 
2. Intracranial complications:  
a. CSF leak 
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b. Meningitis 
c. Abscess and  
d. Intracranial haemorrhage 
3. Nasal complications:  
a. Adhesions formation 
b. Anosmia 
c. Hyposmia and 
d. Lacrimal duct injury. 
ANAESTHETIC TECHNIQUES: 
FESS can be done under monitored local anaesthesia with topical and 
infiltration local anaesthesia or under general anaesthesia with inhalational anaesthesia 
or total intravenous anaesthesia. 
Advantages of monitored local anesthesia: 
• Good hemostasis 
• Clear distinction between healthy and diseased mucosa 
• Rapid wound healing & short recovery time 
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Disadvantages of monitored local anaesthesia: 
• Complicated cases warrant general anaesthesia 
• Airway is not protected 
• Surgeons need to be gentle & proceed with minimal trauma. 
• Anxious patients may need good sedation 
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CONTROLLED HYPOTENSION 
Controlled hypotension or deliberate hypotension during general anaesthesia 
may be employed to lower the mean arterial blood pressure (MAP) in order to reduce 
the intraoperative blood loss. This can be achieved by proper positioning of the patient 
and pharmacological methods. 
Positioning: 
Appropriate positioning of the patient reduces bleeding. To achieve this, the 
operative field needs to be elevated above the level of the heart. This reduces the 
venous pressure and hence the venous bleed. When the head is elevated above the 
level of heart, there is a reduction in venous return, which results in a reduction in 
cardiac output and blood pressure and hence the arterial bleed. 
Pharmacological methods: 
1. Anaesthetic agents: 
a. Volatile anaesthetics 
i. Halothane, 
ii. Isoflurane and 
iii. Sevoflurane 
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b. Intravenous agents: 
i.  Propofol 
2. Vasoactive drugs: 
a. Vasodilators: 
i. Nitroglycerine (GTN),  
ii. Sodium nitroprusside (SNP),  
iii. Hydralazine and  
iv. Purine derivatives 
b. Alpha adrenergic blockers 
c. Beta adrenergic blockers 
d. Combined alpha and beta adrenergic blockers 
e. Calcium channel blockers 
f. Alpha-2 receptor agonists 
A wide variety of drugs have been employed to achieve controlled hypotension 
in a variety of surgeries. These techniques have resulted in lesser blood loss, shorter 
operating time etc., which should have reduced the morbidity associated with such 
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procedures, though they have not been studied. These are relatively non-invasive 
techniques and can be employed by most practitioners relatively safely. 
In a study by Boonmak et al(11) ,the controlled hypotension was given using 
propofol with general anaesthesia for FESS where mean arterial pressure was lowered 
in a range of 50 to 65 mmHg,which had shown good results. 
Controlled hypotension has been helpful in minimising the blood loss and 
improving visibility.In a study by Vazeery et al (19)on patients undergoing total hip 
arthroplasty ,lowering the mean arterial blood pressure by using sodium 
nitroprusside,had shown significant reduction in blood loss as compared to patients 
who did not receive the drug. 
In a study by PP Kadam et al(20) on patients undergoing spine surgery,there 
was significant reduction  in the mean intraoperative blood loss as well as in the 
operating time in the group of patients who were started on Nitroglycerine for 
controlled hypotension. 
Positioning and pharmacological methods when employed together will have 
an additive effect and a good result (23). 
History of hypotensive anaesthesia: 
Controlled hypotension was first proposed by Cushing in 1917 for intracranial 
surgeries (21). Eckenhoff and Rich supplied the objective data that deliberate 
hypotension can indeed reduce the blood loss (22). 
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In 1950’s, ganglion blockade Enderby used pentamethonium was used to 
achieve hypotension (23). In the early 1980’s, volatile agents like halothane as part of 
balanced anaesthesia was used to achieve hypotension by Enderby (24). There have 
been extensive studies using isoflurane for hypotensive anaesthesia (25, 26). After the 
introduction of propofol in anaesthesia, which has good hypotensive potential and has 
the advantage of rapid reversal, total intravenous anaesthesia with propofol (11) also 
has been used for the same purpose. Vasoactive drugs such as SNP (19) and GTN (20) 
and opiates also have been used to achieve deliberate hypotension. Beta blockers (27) 
like metoprolol and alpha blockers like hydralazine have been used (28). 
Centrally acting alpha -2 agonists have also been studied for there hypotensive 
properties and have shown good results (18, 29). These drugs act by various 
mechanisms namely increasing the depth of anaesthesia, which blunts the sympathetic 
response to surgery, cause direct vasodilatation leading to reduced venous return with 
resultant reduction in cardiac output and blood pressure, cause reduction in systemic 
vascular resistance with a resultant reduction in blood pressure, cause direct 
myocardial depression with resultant reduction in cardiac output and consequent 
hypotension. Centrally acting alpha –2 agonists have many of the above properties on 
their own and can potentially be more effective in inducing deliberate hypotension 
under anaesthesia. 
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Indications for hypotensive anaesthesia: 
Microsurgery 
                        Endoscopic sinus surgery 
                        Middle ear surgery 
                        Nerve grafting 
                        Microvascular repair 
                        Plastic surgery e.g. free flap graft 
                        Transnasal transsphenoidal excision 
Complex arteriovenous malformations 
Intracranial surgeries 
Craniofacial surgeries 
Head and neck surgeries 
Spine surgeries 
Pelvic surgeries for malignancy 
Intraocular surgeries 
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Contraindications to hypotensive anaesthesia: 
    Fixed cardiac output state 
Aortic stenosis, 
Mitral stenosis 
Cardiomyopathy 
    Renal impairment 
    Liver dysfunction 
    Pregnancy 
    Peripheral vascular disease 
    Ischaemic heart disease 
    Glaucoma 
    Intracranial hypertension  
    Previous cerebrovascular accident 
    Untreated / uncontrolled hypertension 
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BALANCED ANAESTHESIA 
Balanced anaesthesia (as defined by Mosby's Medical Dictionary, 8th edition) 
is a highly variable technique of general anaesthesia that is based on the concept that 
administration of mixture of small amounts of several neuronal depressants summates 
the advantages but not the disadvantages of the individual components of the mixture. 
This comprises of using narcotic analgesics, muscle relaxants, minimal inhalation 
agent with or without nitrous oxide for anaesthesia balancing the depressant effect on 
motor, sensory, reflex and mental aspects of nervous system function. When 
controlled hypotension is desired for surgery, this technique of balanced anaesthesia in 
combination with various drugs and techniques described earlier will be potentially 
successful with minimal complications. 
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CLONIDINE 
DRUG DESCRIPTION: 
Clonidine is a centrally acting alpha-agonist hypotensive agent. Clonidine 
hydrochloride was synthesized by stahle and associates in 1962 (31). It is a derivative 
of imidazoline that exists as a mesomeric compound. 
Chemical name: 
2-(2, 6dichlorophenylamino)-2-imidazoline hydrochloride  
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Physical properties: 
              Clonidine is a white, crystalline, odorless, bitter substance, soluble in water 
and alcohol. 
Chemical pharmacology: 
Clonidine stimulates the alpha adrenoceptors in the brainstem, which results in 
reduced sympathetic outflow from the central nervous system. This decreases 
peripheral vascular resistance, renal vascular resistance, heart rate and blood pressure 
and cardiac output (32). During long term therapy, cardiac output tends to return to 
control values while peripheral resistance remains reduced (33). 
Clonidine when administered on short-term acutely stimulates growth hormone 
release in both children and adults but does not produce a chronic elevation of growth 
hormone with long-term use. Other studies in patients have provided evidence of a 
reduction in plasma renin activity and in excretion of aldosterone and catecholamines 
(34). The exact relationship of these pharmacological actions to the antihypertensive 
effect of clonidine has not been fully elucidated. Clonidine is available as tablet for 
oral administration, injection form for parenteral administration and transdermal strips 
for transdermal route. 
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Pharmacokinetics: 
Clonidine can be administered via oral, intravenous, intrathecal, epidural and 
transdermal routes. 
• Absorption: 
    Orally administered clonidine undergoes complete 
absorption(35) with a Tmax of about 3 to 5 hours. Intravenously 
administered clonidine has a Tmax of about 19 minutes. When 
administered Transdermally, therapeutic levels are achieved in 2 
to 3 days. 
• Distribution: 
 Volume of distribution (Vd) is about 2.1L/kg. Clonidine is 
about 20% to 40% protein bound. The distribution half life 
(t1/2) of clonidine when administered intravenously is about 11 
minutes.  
• Onset of action:  
 Orally administered clonidine takes about 30 to 60 minutes for 
onset of action with peak effect seen between 2 to 4 hours. 
Intravenously administered clonidine takes 3-15 minutes for 
onset and the peak effect is seen between 35 to 90 minutes (36). 
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• Metabolism:  
 About 50% of the drug is metabolized in the liver. The major 
metabolite is p-hydroxyclonidine. 
• Elimination: 
 Oral route – elimination t 1/2 is 12 to 16 hours. 40% to 60% of 
the drug is excreted unchanged in urine in 24 hours. 
 Intravenous route – elimination t 1/2 is about 9 hours. 72% is 
excreted in urine in 96 hours, out of which 40% to 50% is 
excreted as unchanged drug. Renal clearance is about 133 
minutes. 
 Epidural route – elimination t 1/2 is 22 hours and clearance is 
about 190 minutes. 
 Transdermal route – after removal, therapeutic levels persists 
for about 8 hours declining slowly over several days.  
• Special populations:  
  The elimination t1/2 increases up to 41 hours in those with severe renal 
impairment. In such patients dosage adjustment is recommended. 
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 Indications and usage: 
 Management of hypertension 
 Adjunct to opiates for relief of cancer pain 
 Unlabeled uses: Treatment of constitutional growth in children, diabetic 
diarrhea, Tourette syndrome, alcohol withdrawal, methadone/opiate 
detoxification, ulcerative colitis, diagnosis of phaeochromocytoma, 
neuralgia, hypertensive emergencies. 
Contraindications: 
Hypersensitivity to clonidine 
Pregnancy 
Adverse reactions: 
• Cardiovascular: 
Congestive heart failure 
Orthostatic symptoms 
Palpitations 
Bradycardia 
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• Central Nervous System (CNS): 
Drowsiness 
Delirium 
Nightmares 
Headache 
Fatigue 
• Gastrointestinal: 
Dry mouth 
Constipation 
Anorexia 
Nausea and vomiting 
• Dermatologic: 
Rash and urticaria 
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• Miscellaneous: 
Impotence 
Nocturia 
Muscle cramps 
Drug interactions: 
Clonidine may enhance the depressant effect of alcohol and CNS depressant 
drugs. Clonidine is highly lipid soluble and it crosses the blood brain barrier (37).  
Narcotic analgesics may potentiate the hypotensive effects of clonidine. 
Similarly, the sedative effect of narcotic analgesics may be potentiated by clonidine.  
There is increased possibility of rebound hypertension in patients who are on 
beta-blockers, when clonidine therapy is discontinued.  
Tricyclic antidepressant may reduce the effect of clonidine.  
Clonidine has its effects both at spinal as well as supraspinal levels (38). By 
virtue of this effect, epidural clonidine may prolong the duration of pharmacological 
effect of local anesthetics administered into the subarachnoid and epidural space. 
In recent years, clonidine has generated considerable interest as an anaesthetic 
adjuvant. Being a centrally acting alpha-2 agonist, its use in hypertension and 
hypertensive crisis has been known for many years.  
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Clonidine has proven to be a very good premedication to facilitate induced 
hypotension in adults (18) as well as children (29). The hypotension is mainly due to 
reduction in cardiac output and heart rate without corresponding rise in peripheral 
resistance (33). 
As premedication, clonidine decreases the dose of thiopentone (14) required to 
induce anaesthesia in children as well as reduction in requirement of volatile agent 
(29).  
Thomas Hackmann et al (29) in his study on adolescent children undergoing 
maxillo-facial and oral surgery has shown that patients who received clonidine 
required lesser anesthetics (P=0.0004) and less labetalol for control of blood pressure 
(P=0.004). He also showed that the length of stay in the recovery room was 
significantly shorter in patients who were given clonidine (P=0.03). It was also seen 
that there was no delay in recovery from anaesthesia in patients who received 
clonidine.  
Stocche RM (39) has shown that intravenous clonidine induces hypotension 
without affecting the anesthetic quality and emergence time in tympanoplasty. 
In another randomized, double-blind, placebo-controlled study, Zalunardo et al 
in 1997 (40), the effects of intravenous and oral clonidine on the hemodynamic and 
plasma catecholamine response to endotracheal intubation were observed on 33 
patients. They found that intravenous clonidine reduced the stress response to 
endotracheal intubation compared to placebo. Oral clonidine at the dose of 
4micrograms/kg was less effective in blunting hemodynamic response than 3mcg/kg 
of IV clonidine. 
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Zalunardo et al also concluded in another randomized, double blind, placebo-
controlled trial (41) that a single dose preoperative intravenous dose of clonidine 
(3micrograms/kg) blunts the hemodynamic response during extubation in non-cardiac 
surgery of intermediate duration. 
Clonidine is also known to prolong spinal anaesthesia when added to 
intrathecal local anesthetics (42) or when administered as oral premedication (43). 
Rhee et al (42)  have shown the efficacy of intravenous clonidine in prolonging the 
spinal block by approximately 1 hour without any adverse effects. 
Intravenous clonidine has been proved to be a good hypotensive agent with 
inhalation anaesthesia in a double blind, randomized study by Lee et al (18), on 41 
patients undergoing middle ear and nose surgery. 
Clonidine has shown to be an adjuvant to induce hypotension when used with 
total intravenous anesthesia (17). With inhalational anaesthesia using isoflurane 
clonidine has effectively reduced the isoflurane requirement (44) as well as blood 
pressure (45). 
In many studies it has also decreased the requirement of propofol (46), with 
good cardiovascular stability and postoperative recover y(47). In patients undergoing 
coronary artery bypass surgery (CABG), clonidine has shown to reduce isoflurane and 
nitroglycerine requirement with good cardiovascular stability (48).  The effect of 
clonidine in reducing Sevoflurane requirement for anaesthesia and hypnosis is also 
seen in some studies (49). Thus the requirement of anaesthetic induction agent and the 
maintenance agent is reduced with the use of clonidine. 
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Preoperative clonidine in lower limb surgeries has shown to blunt the 
hyperadrenergic and hyperdynamic responses to prolonged tourniquet pressure during 
general anaesthesia (50). 
Clonidine reduces the presynaptic norepinephrine release, decreases the “set 
point” around which blood pressure is regulated and has a substantial analgesic and 
sedative action (32). Clonidine blunts responses to perioperative stress, which has also 
become a subject of molecular research. In cardiac surgeries like CABG, clonidine use 
has shown significant blunting of stress response during induction of anaesthesia and 
surgical field was better, with the hypotension achieved (48). Clonidine has been used 
as a sedative and as an analgesic too. In mechanically ventilated critically ill patients, 
clonidine has been used as a sedative (51). This sedative action is mainly due to the 
central action of the drug. The analgesic property of the drug has been of great benefit 
in various surgeries for post operative pain relief (52-54) as well as in burn patients 
(55-57). Clonidine causes analgesia by modulation of nociception via the alpha 2 
adrenoreceptors in the spinal cord (58). Peri-operative use of clonidine has also shown 
adjunctive analgesic effects (59). Clonidine also causes the reduction of delirium 
during emergence from sevoflurane anaesthesia (60) and also has been used  
prophylactically in alcohol withdrawal syndrome (61). 
Clonidine decreases the incidence, severity and duration of post-operative 
shivering and therefore the oxygen consumption. It decreases the thermoregulatory 
threshold for vasoconstriction and shivering as hypothalamus has high density of 
alpha-2 receptor. It also acts by reducing the spontaneous firing in locus coeruleus, a 
pro-shivering center in pons (62-64). The effect of reduction in shivering is a decrease 
in postoperative oxygen consumption, as shown by Delaunay et al (65). 
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Like other alpha 2 adrenoceptor agonist, clonidine has side effects like 
bradycardia, hypotension and excessive sedation (47), but these side effects are seen at 
high doses. 
Considering all the above benefits that clonidine provides, it has come up as a 
very useful adjunct in anaesthesia practice today. 
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METHODOLOGY 
This study is a randomized, double blind placebo controlled interventional 
trial. The study was cleared by the research and ethics committee of our institution. 
The sample size was calculated to detect a difference of 40% in hypotension between 
the study groups, sample size was calculated to be 30 in each group. Power of the 
study was assumed to be 80% & level of significance was fixed at 5% 
The inclusion criteria being all adults (18years to 65years) ASA grade I and II patients 
undergoing limited or full FESS. 
The exclusion criteria were: 
• Hypertension on treatment 
• Diabetes with autonomic dysfunction 
• Patients on beta blocker or with contraindication for beta blockers 
• Heart block of any degree / bradyarrhythmias 
• Ischaemic heart disease 
• Patients on pacemakers 
• Patients already on clonidine / allergic to clonidine 
• Pregnant mothers 
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60 ASA I and II patients who were scheduled for FESS were enrolled  in the 
study. A written consent was obtained from the patient on the night before the study. 
Pre-operatively, no sedative premedication was prescribed for the patients.  
Patients were mobilised into the theatre and basic monitoring namely non-
invasive blood pressure, electrocardiogram for heart rate and rhythm and pulse 
oximetry was established. Intravenous line with lignocaine infiltration was secured and 
basal vital signs were recorded. These included non invasive blood pressure, 
electrocardiogram, pulse oximeter and consciousness level. Noninvasive blood 
pressure was monitored every five minutes, which was the standard practice. ECG and 
pulse oximetry were monitored continuously.  
The patients were randomized into two groups using block randomization. All 
patients were assigned to the intervention (clonidine, Group A ) group or comparator 
(placebo Group B) group. Based on randomisation, the patients received 
3micrograms/kg of the drug (Group A) or an equal volume of sterile water for 
injection (Group B) intravenously 30 minutes prior to induction of anaesthesia. The 
vital signs as mentioned previously were monitored for the next 30 minutes.   General 
anaesthesia was induced with intravenous thiopentone (5mg/kg) after fentanyl 
(1.5mcg/kg). After ensuring the ability to ventilate with oxygen, air and isoflurane, 
endotracheal intubation was facilitated with vecuronium (0.1mg/kg). Anaesthesia was 
maintained with oxygen, air and isoflurane. End tidal anaesthetic concentration was 
monitored continuously aiming to maintain a minimum alveolar concentration (MAC) 
of 1.0 of isoflurane during the surgery. If necessary, further doses of fentanyl in 10-20 
mcg aliquots was administered upto a total of 4mcg/kg aiming for a mean arterial 
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pressure (MAP) of 55-65mmHg. Vital parameters were continued to be monitored as 
described till the end of surgery. 
If the target MAP was not achieved after a total of 4mcg/kg of fentanyl and 1.0 
MAC of  isoflurane, metoprolol was administered as 0.5mg boluses to achieve a MAP 
of 55-65mmHg. In spite of the above measures, if the target MAP was not acheived 
and the heart rate was  
< 60/minute, 10mg boluses of propofol was given till MAP was in the desired 
range. This was done to avoid the risk of serious bradycardia with further doses of 
metoprolol.and to standardise the maximum MAC of isoflurane. The side effects 
which were anticipated were bradycardia, hypotension which were common to both 
clonidine and metoprolol. If the heart rate was  
< 50/minute, atropine (0.02mg/kg) was given to treat bradycardia. If the MAP 
< 55mmHg, the inspired isoflurane concentration was reduced by 0.5% till MAC 
reached 0.75. If the blood pressure did not improve with this, ephedrine 3 mg in 
incremental dosage was administered to treat hypotension. 
At the end of the surgery, the anaesthetic was discontinued, throat pack 
removed and residual paralysis was reversed with neostigmine (0.05mg/kg) and 
glycopyrrolate (0.02mg/kg). The patients were extubated when awake and were 
monitored in recovery room. 
Blood loss was estimated by measuring the volume in the suction bottle and the 
number of swabs soaked in blood accounting for any saline used for washing during 
the procedure. At the end of the surgery, the surgeon was requested to comment on the 
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quality of the operation field. Clear field of operation with no suctioning required was 
defined as ‘bloodless’field. Surgeon’s opinion regarding the field of operation was 
assessed by using Fromme-Boezaart scale (66). Sedation was assessed using Brussel’s 
sedation score (67) in the immediate post-operative period. When the patient was fully 
awake, pain was assessed using the visual analogue score (VAS). 
Fromme-Boezaart scale 
Assessment of intra-operative bleeding  
Grade 0: No bleeding. 
Grade 1: Slight bleeding, no suctioning of blood required. 
Grade 2: Slight bleeding, occasional suctioning required. Surgical field not threatened. 
Grade 3: Slight bleeding, frequent suctioning required. Bleeding threatens surgical 
field a few seconds after suction is removed. 
Grade 4: Moderate bleeding, frequent suctioning required, bleeding threatens surgical 
field after removal of suction. 
Grade 5: Severe bleeding, constant suctioning required, bleeding appears faster than 
can be removed by suction, surgical field severly threatened and surgery impossible. 
               A : Excellent (grade 0-1) 
B : Good (grade2-3) 
C : Poor (grade4-5) 
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Brussel’s Sedation score 
1. Unarousable. 
2. Responding to pain stimulation (trapezius muscle pinching) & not to auditory 
stimulation. 
3. Responding to auditory stimulation 
4. Awake and calm 
5. Agitated 
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STATISTICAL ANALYSIS 
All normally numerical variables were summarized using mean with 
SD(standard deviation). Variables with skewed distributions were described using 
median and range.  
The outcome variables were compared between the two study groups using 
chi-square test.  
All calculated p-values were two-sided. Analysis was done using STATA 10.0 
(Statacorp, College station, TX, USA).  
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RESULTS 
Sixty patients undergoing (FESS) were included in the study. There were thirty 
in each group. 
Table 1 shows the demographic data of the patients. The age, gender and body 
weight were comparable between the two groups. 
Figure 1 
0
20
40
60
80
100
Pe
rc
en
ta
ge
GroupA Group B 
Male Female
35 
 
Table 1 
Demographic Data 
Parameters GROUP A (n=30) GROUP B (n=30) P value 
Age (years) 
Mean± S.D. 
 
37.13 ± 10.78 
 
37.4 ± 12.82 
 
0.93 
Sex:     Male 
Female 
18 (60%) 
12 (40%) 
22 (73.33%) 
8 (26.67%) 
 
0.273 
Body weight (kg) 
Mean± S.D. 
60.13 ± 11.91 60.76 ± 12.38 0.85 
 
The above table shows male predominance in both the groups respectively 
60% and 73.33%.  The p value is 0.273.  
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Figure 2 
Preoperative Diagnosis: 
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Table 2 
Preoperative Diagnosis: 
DIAGNOSIS GROUP A GROUP B 
Chronic sinusitis 15 (50%) 17 (56.66%) 
Nasal polyposis 15 (50%) 13 (43.33%) 
Fisher’s exact = 0.8 
• There were equal number of patients in group A with the preoperative 
diagnosis of chronic sinusitis and nasal polyposis, whereas in group B chronic 
sinusitis was seen more than nasal polyposis. 
• There was no statistical difference in the number of patients with the two 
diagnoses in group B. 
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Figure 3 
Success of achievement of controlled hypotension with clonidine alone 
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Table 3 
Success of achievement of controlled hypotension with clonidine alone 
 GROUP A GROUP B 
Successful 14 (46.6%) 2 (6.66%) 
Not successful 16 (53.3%) 28 (93.3%) 
 
“P” value < 0.001 
• At induction 1.5 mcg/kg of fentanyl was administered to all the patients. In 14 
out of 30 patients (46.6%) in the clonidine group, target blood pressure was 
achieved without additional fentanyl and metoprolol. In the placebo group, 
target blood pressure was achieved only in 2 (6.66%) out of 30 patients with 
the induction dose of fentanyl. 28 (93.3%) patients needed additional fentanyl 
and metoprolol. This difference was statistically significant. 
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Table 4 
Requirement of additional fentanyl to achieve target blood pressure 
 GROUP A GROUP B 
Required 16 (53.3%) 28 (93.3%) 
Not required 14 (46.6%) 2 (6.66%) 
 
 (P value <0.001) 
• 16 (53.3%) patients out of 30 who received clonidine, required additional 
fentanyl (after the 1.5mcg/kg induction dose) up to a total 4mcg/kg for 
achieving blood pressure within the target range. In the placebo group, 28 
(93.3%) patients out of 30 needed fentanyl up to 4mcg/kg to achieve target 
blood pressure. This difference was statistically significant. 
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Table 5 
Requirement of Metoprolol 
Metoprolol GROUP A GROUP B 
Required 3 (10%) 22 (73.3%) 
Not required 27 (90%) 8 (26.6%) 
 
(P value < 0.001) 
• Metoprolol was administered if the target blood pressure was not achieved 
after administration of a total of 4mcg/kg of fentanyl and MAC of isoflurane 
was 1.0. In the placebo group 22 (73.3%) out of 30 patients required 
metoprolol as an additional drug to achieve hypotension within the target 
range, which was significantly higher than the clonidine group where only 8 
(26.6%) of the patients needed metoprolol. 
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Table 6 
“Bloodless” field during the surgery 
 GROUP A 
(n = 30) 
GROUP B 
(n = 30) 
P 
Value 
Bloodless Field 11 (36.67%) 3 (10%) 0.05 
 
• There was significant difference in successful achievement of bloodless field 
between the two groups with more success in the clonidine group. 
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Table 7 
Intraoperative blood loss (millilitre) 
 GROUP A GROUP B P 
Median blood loss 
     (Range) 
63.5 
(40-200) 
180 
(70-300) 
0.0449 
 
• Median blood loss in the patients who received clonidine was 63.5 ml, which 
was significantly lower that the placebo group with a median blood loss of 180 
ml. 
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Table 8 
VAS (visual analogue scale) for assessment of pain 
 GROUP A GROUPB P value 
Mean (SD) 
Median (Range) 
0.27 (0.73) 
0 (0-3) 
0.93 (1.28) 
0 (0-5) 
 
0.01 
 
• Patients who received clonidine had significantly better analgesia in the 
immediate post-operative period. 
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Table 9 
MAC (minimum alveolar concentration) of isoflurane 
 GROUP A GROUP B P value 
MAC (60min) 
i.e.  < 1 
5 
(16.6%) 
1 
(3.3%) 
0.0837 
 
• Out of 60 patients, only 6 patients required the anaesthetic at a lower 
concentration at one set point of time. 
• Therefore there was no significant difference in the requirement of anaesthetic 
agent in both the groups. 
 
 
46 
 
Figure 10  
Complications 
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 Over sedation was seen in 6.67% of patients in group A whereas 10% 
of patients in Group B. 
 Hypotension requiring treatment was seen in 33.33% of patients in 
Group A whereas 30% of patients in group B.
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Table 10 
Complications 
 GROUP A GROUP B P value 
Over sedation 2 
(6.67%) 
3 
(10%) 
0.640 
Hypotension 10 
(33.33%) 
9 
(30%) 
0.781 
Bradycardia 1 
(3.33%) 
0 
(0%) 
0.313 
 
• The complication rate of excessive sedation, bradycardia and hypotension 
requiring treatment was not significant between both the groups.                       
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DISCUSSION 
Controlled hypotension is a very useful technique in surgeries where a 
bloodless field is expected. Hypotensive techniques are used widely in anaesthesia 
practice in cases where major blood loss may occur or to aid a “bloodless surgical 
field”. Volatile anaesthetic based anaesthetic techniques and total intravenous 
anaesthetic technique has been in use for many years. 
However, the need of better results and improvement in the surgical field has 
always been a reason for further research. This has led to studies on many other drugs 
for achieving controlled hypotension. Clonidine, a hypotensive agent belonging to 
alpha 2 agonist class of drugs, has come up with promising results in achieving 
bloodless field when used with balanced anaesthesia. It also has other benefits like 
analgesia, sedation and reduction in anaesthetic requirement. This study was designed 
to evaluate the hypotensive effect of clonidine when used with balanced anaesthesia, 
along with its other benefits, especially in our Asian population. 
In our study, target MAP of 55-65mmHg was achieved in 46.6% of the patients 
in the clonidine group versus 6.7% the placebo group with just the induction dose of 
fentanyl (1.5 mcg/kg). Moreover, only 53.3% of patients in the clonidine group versus 
93.3% in the placebo group needed extra fentanyl (up to a total dose of 4mcg/kg) to 
achieve the target MAP. The use of rescue drug metoprolol was 10% in clonidine 
versus 73.3% in the placebo group. Thus clonidine is effective to achieve controlled 
hypotension as part of balanced anaesthetic technique. These observations are similar 
to the study done by Lee et al (18) and Hackmann et al (29). However there were few 
patients in both the (2 in clonidine and 3 in placebo) groups, who required propofol for 
49 
 
achieving the target MAP, despite using metoprolol. In a study by Lee et al(18) 46 
patients were studied to compare the hypotensive effect of clonidine with placebo in 
middle ear and nose surgery. There aim was to achieve a systolic blood pressure of 
80mmHg.It was seen that there was no difference in MAP in the two groups before 
and during anaesthesia, except in the values at the 45 minute of surgery in both groups 
where reduction in MAP was found to be significant.  
As regard to the requirement of additional fentanyl ,there were only 16 patients 
in clonidine group that required fentanyl whereas in placebo group 28 patients out of 
30 required fentanyl. This is similar to the studies done on clonidine to emphasize its 
effect in reducing the requirement of fentanyl, isoflurane and beta blockers(study by 
Hackmann et al(29) on adolescent children to investigate whether clonidine lessened 
the requirement of fentanyl, isoflurane and labetalol) except that our study did not 
show significant reduction in isoflurane requirement. 
In a study by Mandal et al(8), hypotensive anaesthesia was achieved in 30 
patients undergoing FESS using isoflurane. MAP of 55-60mmHg was aimed in this 
study for which mean inspired isoflurane used was 3.8%. 
We had set a maximum MAC of 1.0 for isoflurane whereas other studies have 
used a higher MAC. There was no reduction in the requirement of isoflurane for 
maintenance of anaesthesia with the use of clonidine. This may be due to the 
maximum limit we had set. 
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There was no significant difference between the two groups in terms of heart 
rate measured at different time intervals as opposed to the study done by Nair, Salil et 
al (27) where beta blockers were used for hypotension in FESS. Their study showed a 
significant difference in overall mean heart rate between the placebo and the beta-
blocker groups (p<0.0001). 
Concomitant use of fentanyl was seen somewhat equally in both the groups 
without any large difference. 
In our study, the blood loss was less in the clonidine group. As seen in a study by 
Mandal et al there was significant difference in the intraoperative blood loss. Mandal 
et al found that hypotensive anaesthesia with isoflurane resulted in less bleeding 
compared to normotensive anaesthesia provided by isoflurane. In our study ,it was 
seen that many patients achieved controlled hypotension in clonidine group with mean 
blood loss of 63.5ml(40-200ml),whereas in placebo group with mean blood loss of 
180ml(70-300ml),which was statistically significant. 
 Though the target blood pressure was achieved in both the groups, the placebo 
group needed more fentanyl and metoprolol to achieve the target MAP. Thus the MAP 
in the placebo group was higher most of the time (though it was brought to target level 
ultimately) causing more blood loss. We classified the grading of surgical field as 
poor, good and excellent based on the Fromme-boezaart scale of surgical field 
grading. Clonidine group had significantly excellent surgical field of operation when 
compared to the placebo group (P =0.05). 
Post-operative analgesia was better in patients who received clonidine. It was 
found that patients who received clonidine had much lesser pain score than the ones 
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who did not receive the drug. Clonidine group demonstrated the range of (0-3) on 
VAS whereas placebo group had VAS score range of (0-5), which was significant. 
Sedation score was found to be comparable in both the groups. The anaesthetic 
concentration was titrated using the anaesthetic gas analyzer, towards the time of 
extubation. Excessive sedation was seen in very few patients in both the groups, 
results of which did not show any significance. The other complications like 
hypotension and bradycardia requiring treatment were comparable in both the groups.    
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CONCLUSIONS 
Clonidine when used in a dose of 3mcg/kg intravenously 30 minutes prior to induction 
of anaesthesia in FESS 
 Is effective in achieving controlled hypotension when used with balanced 
anaesthesia in FESS. 
 Is effective in reducing the intra-operative requirement of additional fentanyl 
and metoprolol. 
 Effectively reduces the intraoperative blood loss and offers a conducive 
operating field. 
  Provides good analgesia property. 
 Is devoid of serious hypotension, bradycardia and does not cause over sedation 
prolonging the recovery time. 
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PROFORMA 
                                                                                                                  Serial number: 
(INTRAVENOUS CLONIDINE AS HYPOTENSIVE AGENT IN ACHIEVING 
CONTROLLED  HYPOTENSION IN FUNCTIONAL ENDOSCOPIC SINUS 
SURGERY) 
 
 
Name:                                                                 Hospital no.: 
 
Age:                                            Sex:                                         Weight: 
 
Clinical diagnosis: 
 
NO  PREMEDICATIONS. 
 
MONITORS : Pulse oxymetry    
                        Non invasive bloodpressure(NIBP) 
                        Electrocardiogram(ECG) 
                        End tidal carbondioxide 
                        Gas analyzer for minimum alveolar concentration(MAC) 
 
IV CLONIDINE /PLACEBO : 3mcg/kg  to be administered 30 minutes before 
induction 
                                                  in anaesthesia room 
 
PREOXYGENATION: with 100% oxygen  
 
IV INDUCTION :  Fentanyl                1.5mcg/kg 
                               Thiopentone           5 mg/kg 
                               Vecuronium           0.1mg/kg 
                               Endotracheal intubation with appropriate size tube 
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MAINTENANCE:  
• O2 + AIR +ISOFLURANE(maintaining MAC as 1.0) 
• IV Paracetamol 15mg/kg 
• IV Fentanyl to be administered in aliquots of 10-20 mcg(upto a total of 
4mcg/kg) for control of MAP between 55-65mmHg 
• If MAP  control is not achieved after a total of 4mcg/kg of fentanyl then 
Metoprolol in 0.5mg boluses to be administered to achieve MAP of 55-
65mmHg 
• If MAP<55mmHg inspired isoflurane to be reduced by 0.5% till MAC reaches 
0.75 
• If blood pressure does not improve,ephedrine 3mg  in incremental dosage will 
be given 
• If the heart rate <50/minute,atropine(0.02mg/kg)will be given 
• IV Ondansetron 0.1mg/kg to be administered just before extubation 
EXTUBATION:  
• Anaesthetic to be discontinued  at the end of the procedure 
• Reversal agent:Neostigmine(0.05mg/kg) 
                                                   + 
                               Glycopyrrolate(0.01mg/kg)  
• Patient to be extubated when he/she is awake 
 
MONITORING:  
                            baseline         pre-induction   (Q 5 min till 30 min.)   
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              --------------------------------------------------------------------------------------------                          
                                                  0min  5min  10min  15min  20min  25min  30min     
              --------------------------------------------------------------------------------------------- 
                SBP  
               -------------------------------------------------------------------------------------------- 
                DBP 
              --------------------------------------------------------------------------------------------- 
                MAP 
              --------------------------------------------------------------------------------------------- 
                HR 
              --------------------------------------------------------------------------------------------- 
                             At induction                  Q 5 minutes till extubation                                                           
              ----------------------------------------------------------------------------------------------      
10  15  20  25  30  35  40  45  50  55  60  65  70  75 
             ---------------------------------------------------------------------------------------------- 
                SBP 
              --------------------------------------------------------------------------------------------- 
                DBP 
             ---------------------------------------------------------------------------------------------- 
                MAP 
             ---------------------------------------------------------------------------------------------- 
                 HR 
             ---------------------------------------------------------------------------------------------- 
                MAC 
             ----------------------------------------------------------------------------------------------  
                            80  85  90  95  100  105  110  115  120               Postextubation 
             ---------------------------------------------------------------------------------------------- 
                SBP 
             ---------------------------------------------------------------------------------------------- 
                DBP 
             ---------------------------------------------------------------------------------------------- 
                MAP 
             ---------------------------------------------------------------------------------------------- 
                 HR 
             ---------------------------------------------------------------------------------------------- 
                MAC 
             ---------------------------------------------------------------------------------------------- 
 
INTRAOP BLOOD LOSS:    swabs soaked in blood = 
                                                Suction blood               = 
                                                 Total                            = 
 
PAIN SCORE :   (Visual analogue score) 
 
SEDATION SCORE:     1)Unarousable. 
   (Brussel’s )                   2)Responding to pain stimulation(trapezius muscle  pinching) 
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                                & not to auditory stimulation.  
                                  3)Responding to auditory stimulation 
                                  4)Awake and calm 
                                  5)Agitated 
 
  COMPLICATIONS: (if any,please tick ) 
1. Hypotension requiring ephedrine 
2. Bradycardia requiring atropine 
3. Sedation score of 3 
 
Surgeon’s opinion about the surgical field-Fromme-Boezaart scale : (please tick) 
 
a. Excellent(grade0-1) 
b. Good(grade 2-3) 
c. Poor(grade4-5) 
                                                    
Total dose of metoprolol in milligrams (if used): 
 
Total dose of fentanyl in micrograms : 
 
(SBP:systolic blood pressure  DBP:diastolic blood pressure 
 HR:heart rate 
 MAP:mean arterial pressure 
 MAC:minimum alveolar concentration)  
 
Total dose of propofol used in milligrams(if used):       
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Christian Medical College, Vellore 
Department of Anaesthesia 
A randomized trial comparing the hypotensive effect of clonidine with placebo 
in patients undergoing Functional endoscopic sinus surgery (FESS). 
Information   sheet 
You are being requested to participate in a study to see if a drug called 
clonidine is able to reduce your blood pressure successfully within a given range 
during the sinus surgery which you will be undergoing. 
This surgery involves blood loss that can make visibility of the surrounding 
structures difficult for the operating surgeon and thereby can lead to complications. 
Lowering the blood pressure can minimize this blood loss and thus offers good result. 
What does clonidine do? 
Clonidine lowers the blood pressure and heart rate .It has been in use for the 
treatment of high blood pressure patients. This drug also has pain relief quality as well 
as provides mild sedation. 
Does it have any side effects? 
Clonidine has been in use for many years in the treatment of high blood 
pressure. The side effects have been noticed when it has been stopped suddenly after a 
long term therapy or if taken in a very high dose than what we plan to use in this 
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study. These side effects are like drowsiness, dry mouth, low heart rate, low blood 
pressure, nausea and headache. 
If you take part what will you have to do? 
If you agree to take part in this study, then on the day of the operation you will 
be given either clonidine or an identical looking drug i.e. a dummy drug through an 
intravenous cannula which will be introduced in one of your hand veins and will also 
be used to give saline or other drugs. This cannula is routinely put for all patients 
undergoing any type of surgeries. Using this dummy drug will help us to know that 
successful lowering of blood pressure within a given range has been by clonidine and 
not due to chance. 
However patients who will be subjected to the dummy drug will also not suffer 
harm because another drug called Metoprolol will be used as a rescue medication in 
both the groups in case the fall in BP is not possible within a given range. Neither you 
nor your doctor giving anaesthesia will have a choice in whether you get clonidine or 
dummy drug as this will be decided by a computer generated program. Also neither 
you nor your doctor will know which drug you got out of the two till the study is over. 
Once you are given the assigned drug your BP, heart rate and breathing will be 
under continuous monitoring. After this you will be subjected to general anaesthesia in 
a usual way that is applied for this surgery during which your BP, heart rate oxygen 
saturation and breathing will be strictly monitored by an anesthetist. Once your 
operation is over you will be woken up and shifted to recovery room where you will 
be again kept under monitoring till you are fully awake and then will be sent back to 
your respective ward. 
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If you choose to withdraw from the study,then, clonidine or the dummy drug 
will not be administered to you prior to anaesthesia,instead you will be subjected to 
anaesthesia in the usual way which is practiced routinely for FESS patients and other 
drugs like metoprolol etc. will be used for lowering the blood pressure during the 
surgery. 
Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you can withdraw 
from this study anytime before you are subjected to anaesthesia. If you do so, this will 
not affect your usual treatment at this hospital in any way. In addition, if you 
experience any serious side effect or your condition worsens, the study drug will be 
stopped and you may be given additional treatment. 
What will happen if you develop any study related injury? 
We do not expect any injury to happen to you but if you do develop any side 
effect or problems during the study, these will be treated at no cost to you. We are 
unable to provide any monetary compensation, however. 
Will you have to pay for the study drug? 
Both clonidine and the dummy drug will be given free of cost to you. The other 
expenses related to the surgery and the anaesthesia will have to be paid by you as 
usual. 
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What happens after the study is over? 
You may benefit from the study that your blood loss would have got 
minimized and complications would have been avoided. The result however will 
however help us to know that clonidine can be used in future for lowering the BP 
within a given range in patients undergoing FESS 
Will your personal details be kept confidential? 
You will never be identified by name in any publications or presentation of the 
results of this study. However your medical notes may be reviewed by people 
associated with the study without your additional permission, should you decide to 
participate in this study. 
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CONSENT   FORM 
 
Study title:  A randomized trial comparing hypotensive effect of clonidine with 
placebo in patients undergoing functional endoscopic sinus surgery (FESS). 
 
Study no.: 
Participant’s name: 
Date of birth/Age(in years): 
 
I______________________________________________________son/daughter of 
_________________________________________ 
 
(Please tick boxes) 
Declare that I’ve read the information sheet provided to me regarding this study and 
have clarified any doubts that I had. (  ) 
I also understand that my participation in this study is entirely voluntary and that I am 
free to withdraw permission to continue to participate at anytime prior to 
administration of anaesthesia without affecting my usual treatment or my legal rights.  
(  ) 
I also understand that neither I, nor my doctors ,will have any choice or knowledge of 
whether I will get clonidine or the identical looking dummy drug.  (  ) 
I understand that I will receive free treatment for any study related injury or adverse event 
but I will not receive any other financial compensation.  (  ) 
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I understand that the study staff and institutional ethics committee members will not need my 
permission to look at my health records even if I withdraw from the trial. I agree to this access.  
(  ) 
I understand that my identity will not be revealed in any information released to third parties 
or published.  (  ) 
I voluntarily agree to take part in this study.  (  ) 
 
Name: 
Signature: 
Date: 
 
Name of witness: 
Signature: 
Date: 
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KEY TO DATA ENTRY SHEET 
 
Group A = Clonidine 
Group B = Placebo 
Hosp.No.= Hospital number 
MAP-PB = mean arterial blood pressure-preinduction(baseline) 
P ( 0 to 30 min)=preinduction MAP at different time intervals 
INDUC= Induction 
EXTUB=Extubation 
SBP-B=Systolic blood pressure(baseline) 
DBP-B=Diastolic blood pressure(baseline) 
HR-B=Heart rate(baseline) 
HR-IND=Heart rate at induction 
MAC-ind=Minimum alveolar concentration at induction 
Bl.loss=Blood loss(ml) 
VAS=Visual analog score 
Sed.score= Sedation score 
Metop=Metoprolol(mg) 
Fenta=Fentanyl(mcg) 
Addtn.fenta=Additional fentanyl 
Profol=Propofol(mg) 
FIELD=Surgical field grading 
CompEph=complication(hypotension requiring ephedrine) 
CompAtr=complication(bradycardia requiring atropine) 
CompSed=complication(over sedation) 
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1 A 754763 39 F 60 b/lsinonasal polyp 87 88 84 83 73 73 73 72 68 69 62 66 59 61 64 62 63 63 63 67
2 A 524441D 45 F 51 b/lsinonasal polyp 75 72 66 65 63 63 62 65 56 54 58 55 63 54 55 60 63 63 63 58
3 B 515971D 52 M 52 b/lsinonasal polyp 85 82 82 83 87 88 87 85 95 73 91 77 78 70 73 75 72 71 70 65
4 B 526743D 53 M 51 Chronic Sinusitis 78 80 86 84 85 84 86 86 94 69 54 76 67 74 67 59 63 65 64 64
5 A 556634D 49 M 63 b/lsinonasal polyp 98 92 84 86 77 77 83 84 69 62 78 65 54 60 54 72 64 66 60 77
6 B 917280C 18 M 94 b/lsinonasal polyp 89 86 92 83 83 88 92 83 105 91 79 64 65 81 69 67 68 66 72 66
7 B 479114D 32 M 55 Chronic Sinusitis 68 71 67 67 68 66 75 73 75 70 67 70 61 64 63 67 63 62 63 66
8 A 126299A 30 M 78 Chronic sinusitis 93 89 87 84 76 83 83 85 60 84 72 64 64 58 56 50 67 61 55 56
9 A 542656d 25 M 75 Chronic sinusitis 77 74 74 74 70 74 78 88 66 75 71 69 60 61 58 65 64 68 61 58
10 B 136251D 27 M 63 Chronic sinusitis 74 74 72 72 74 72 71 86 54 91 68 68 64 59 64 56 55 60 65 64
11 A 398343d 33 F 40 b/lsinonasal polyp 76 76 71 68 67 68 68 76 68 57 67 65 70 67 69 64 63 60 59 70
12 A 398474D 53 M 50 Chronic sinusitis 70 70 68 68 64 64 63 70 80 68 67 64 60 59 54 48 52 53 50 54
13 B 485009D 24 M 74 Chronic Sinusitis 67 68 68 64 68 65 64 74 71 68 96 72 87 70 70 65 66 71 70 83
14 B 772502D 22 M 57 Chronic Sinusitis 78 78 78 76 76 79 78 79 66 100 79 75 71 74 69 68 66 66 63 62
15 A 579524C 43 M 80 Chronic Sinusitis 99 98 89 88 88 86 84 84 89 112 86 82 76 75 79 84 83 85 79 76
16 B 492729D 38 M 54 Chronic Sinusitis 74 70 72 73 72 72 71 73 80 77 72 66 74 70 56 56 54 58 59 57
17 A 091878C 24 M 64 Chronic Sinusitis 78 80 76 72 70 68 68 73 65 68 65 64 64 65 64 60 60 60 60 60
18 B 445949D 26 M 60 Chronic Sinusitis 85 85 90 81 72 99 85 80 103 93 79 81 92 72 69 71 72 112 72 64
19 B 430354D 28 M 55 Chronic Sinusitis 102 102 95 96 93 93 104 86 81 76 66 63 64 65 65 67 64 63 75 59
20 A 527025D 26 M 54 Chronic Sinusitis 83 72 77 71 64 70 65 76 74 70 86 66 59 57 60 59 58 62 62 65
21 A 273723D 56 F 54 Chronic Sinusitis 112 101 84 82 79 78 78 95 78 57 57 64 58 57 43 54 55 55 59 60
22 B 119201D 37 M 80 Chronic Sinusitis 79 72 75 73 73 78 80 84 70 65 75 70 67 64 68 70 55 58 66 65
23 A 713802C 49 M 55 Chronic Sinusitis 95 85 79 78 79 70 71 79 60 67 73 70 63 61 52 60 59 50 67 65
24 A 585410D 40 F 45 b/lsinonasal polyp 89 89 81 82 76 75 73 76 56 80 71 59 61 59 57 62 63 61 67 62
25 B 575831D 32 M 70 Chronic Sinusitis 99 90 90 91 95 91 90 90 90 90 82 75 68 62 63 60 68 62 57 62
26 A 165237C 43 M 50 b/lsinonasal polyp 84 84 82 71 68 62 68 70 59 74 56 58 60 61 55 58 57 64 55 54
27 B 538422d 33 M 63 b/lsinonasal polyp 76 72 71 76 76 70 80 94 85 78 79 61 61 65 78 63 65 61 59 61
28 B 575671d 18 M 60 Chronic Sinusitis 79 75 78 79 78 75 75 76 61 60 73 57 60 54 59 55 55 53 52 57
29 B 587385d 60 F 44 b/lsinonasal polyp 100 100 98 98 96 98 98 108 63 62 62 62 63 64 56 60 64 60 61 58
30 A 579548d 22 M 50 Chronic Sinusitis 82 82 90 77 73 71 67 71 56 77 75 58 66 58 56 57 58 64 60 63
31 A 619236d 22 M 64 b/lsinonasal polyp 66 65 66 64 63 64 68 79 75 64 61 63 63 67 63 58 60 61 57 64
32 B 547810D 49 M 63 b/lsinonasal polyp 90 94 89 94 86 93 94 94 54 73 58 52 71 60 74 89 53 77 66 63
33 A 797256C 40 F 75 b/lsinonasal polyp 79 74 82 66 69 67 69 78 59 83 69 70 67 68 66 63 63 64 63 64
34 B 251319d 21 M 55 Chronic Sinusitis 100 97 97 95 98 98 100 100 72 97 80 100 60 56 52 57 55 56 66 55
35 B 618755D 47 F 50 b/lsinonasal polyp 114 108 106 111 109 104 100 114 55 100 72 53 65 48 47 52 65 55 49 76
36 B 389191D 42 M 80 b/lsinonasal polyp 112 108 102 105 101 99 101 128 98 112 95 81 83 75 66 64 61 60 69 69
37 A 602186d 50 M 63 b/lsinonasal polyp 87 81 77 77 71 72 71 80 59 69 64 45 55 47 49 55 48 53 53 51
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38 A 523226d 45 F 61 Chronic Sinusitis 82 82 64 61 64 65 68 75 53 71 56 61 58 58 56 58 65 70 66 58
39 A 594165d 23 M 41 b/lsinonasal polyp 74 74 74 71 70 71 71 79 62 61 57 58 59 54 59 53 57 60 60 59
40 B 849853C 26 F 50 b/lsinonasal polyp 71 68 62 68 66 65 73 70 74 78 62 63 65 60 49 59 59 62 58 61
41 A 534234d 32 M 55 Chronic Sinusitis 74 68 68 65 71 71 62 61 55 72 58 56 56 64 62 58 56 64 61 59
42 B 623581d 31 M 60 b/lsinonasal polyp 82 82 82 82 80 82 94 83 75 89 80 74 75 88 88 77 92 77 92 88
43 B 496928D 28 M 50 b/lsinonasal polyp 79 77 77 70 73 77 78 90 98 79 72 65 62 63 60 65 63 54 57 57
44 A 720668C 40 F 76 Chronic Sinusitis 77 73 72 78 78 80 80 68 75 75 67 57 55 48 48 68 69 56 56 55
45 B 523237D 48 M 46 Chronic Sinusitis 63 58 63 62 62 65 58 80 55 42 63 64 58 55 53 50 55 55 56 55
46 A 628473D 28 F 50 b/lsinonasal polyp 76 63 63 56 58 64 60 62 61 55 56 55 55 62 61 56 55 60 59 65
47 B 640177d 33 F 50 b/lsinonasal polyp 89 88 80 78 74 70 70 69 59 66 65 63 62 61 67 59 60 60 60 59
48 A 624734D 32 M 80 Chronic Sinusitis 70 63 63 63 64 63 64 69 78 77 76 74 67 68 68 64 66 67 65 54
49 A 538342D 33 M 78 Chronic Sinusitis 88 64 64 65 63 73 67 85 70 105 102 76 74 63 60 60 55 70 84 66
50 B 334070C 56 F 64 Chronic Sinusitis 90 88 90 86 89 88 88 85 90 75 54 69 71 79 69 63 66 65 52 55
51 B 624250D 59 F 73 Chronic Sinusitis 105 100 100 100 104 101 101 124 88 67 60 64 64 60 59 56 55 61 79 78
52 A 610172D 45 F 70 b/lsinonasal polyp 93 87 87 85 84 80 76 73 86 86 78 56 66 64 64 64 52 65 65 64
53 B 073389B 48 F 68 Chronic Sinusitis 104 100 100 98 99 96 90 96 70 69 71 80 65 65 66 62 57 64 63 54
54 A 482703D 20 M 51 Chronic Sinusitis 74 67 64 64 76 67 60 56 64 64 76 67 60 56 56 55 61 60 63 56
55 B 636380D 57 M 48 b/lsinonasal polyp 89 88 89 90 86 88 88 89 74 103 77 74 70 68 70 64 63 62 57 55
56 B 299970D 41 F 50 Chronic Sinusitis 70 68 69 69 70 70 68 74 70 66 63 60 56 54 67 66 66 66 65 63
57 A 566125D 30 F 50 b/lsinonasal polyp 84 87 80 78 64 69 69 72 64 64 54 56 57 60 62 62 64 70 64 60
58 A 619796D 56 F 56 b/lsinonasal polyp 103 104 116 102 98 96 96 107 100 72 92 68 65 64 78 74 59 63 62 62
59 A 577878D 41 M 65 b/lsinonasal polyp 82 71 68 66 64 64 64 72 70 69 71 72 68 66 65 65 66 65 67 68
60 B 571758D 36 M 84 b/lsinonasal polyp 106 104 100 98 104 104 100 112 114 112 100 69 65 76 66 77 65 65 65 57
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69 64 63 63 64 64 64 63 63 67 86 133 129 102 109 99 99 99 90 82 99 9 74 80 93 88 97 104 86
63 64 65 69 76 77 77 76 80 110 103 100 99 95 95 95 90 86 80 76 79 82 80 80 80 86 86
62 72 74 68 66 65 77 74 77 78 78 77 78 108 107 108 110 117 117 116 112 115 99 116 107 103 110 97 106 100 107
63 65 65 55 52 73 68 70 61 60 61 62 84 110 107 110 108 110 108 110 110 129 83 70 98 86 94 87 80 77 85
66 60 65 63 69 77 56 58 58 65 69 68 74 119 128 126 117 116 102 102 99 95 95 89 89 88 86 84 90 89 88
71 65 66 83 81 73 62 62 92 125 120 118 121 121 120 124 115 130 119 105 96 92 111 105 103 101 105
65 63 63 63 64 63 66 67 71 103 106 105 100 101 101 107 106 97 95 102 97 87 95 91 91 91 95
57 63 56 57 65 61 62 56 60 65 62 65 85 125 125 119 128 119 108 117 126 85 111 96 92 82 82 75 79 79 77
60 68 65 68 68 70 63 61 61 77 117 111 109 103 102 110 110 114 91 103 107 98 103 95 94 86 87 80
67 69 62 57 58 70 64 55 73 69 61 61 84 114 114 110 110 112 110 110 119 101 124 107 119 105 102 99 94 94 106
80 73 70 65 69 68 69 69 73 109 109 98 87 87 90 90 109 93 83 91 100 90 90 92 90 90 88
58 65 57 57 57 54 64 55 62 65 65 66 76 104 104 102 99 98 98 99 108 116 95 88 86 86 84 70 74 76 78
84 70 67 67 65 65 64 70 83 105 105 107 108 106 101 104 122 106 103 134 108 127 113 107 103 102 110
62 65 66 66 65 65 65 64 65 65 65 74 91 117 113 112 109 109 117 117 122 105 105 131 114 110 106 110 111 104 100
76 71 70 69 66 66 65 65 68 66 83 138 129 121 105 105 112 114 118 119 13 113 108 112 108 112 114 119 113
56 60 67 60 60 60 65 66 66 65 72 114 117 116 114 114 116 116 114 105 106 88 87 97 88 82 78 72 82
58 60 62 64 65 65 65 68 80 112 108 107 103 103 100 100 101 93 89 100 95 95 92 109 95 95 92
70 70 76 66 65 65 65 65 70 74 87 129 120 124 112 105 123 123 116 121 107 112 105 123 104 103 103 103 158
61 60 61 73 80 153 142 13 148 131 147 147 121 116 108 100 104 103 103 99 101 96 94
59 59 59 70 74 74 77 122 115 116 113 109 106 105 111 93 97 111 113 90 87 92 87 84 93
56 51 54 53 57 70 90 104 155 139 107 106 101 100 99 124 102 78 78 90 78 78 68 77 77 77
67 42 52 76 55 66 61 69 63 55 77 120 112 118 115 115 117 119 122 104 94 108 99 95 105 115 102 105 98
63 62 59 56 61 61 88 135 119 112 111 112 100 101 112 89 95 105 99 81 82 72 87 88 70
64 64 64 63 65 65 89 117 118 109 108 98 98 100 98 76 104 92 82 84 82 77 83 84 84
69 63 71 59 60 62 62 69 84 113 111 110 112 113 112 111 112 134 119 109 98 102 89 90 90 92 85
61 58 55 54 55 62 64 64 88 114 114 109 104 98 92 92 98 88 101 88 80 94 89 86 88 85 93
60 65 65 64 65 65 88 114 112 104 115 114 104 116 116 138 118 110 104 92 92 97 97 100 94
61 58 56 76 68 61 64 65 67 59 60 62 80 111 104 110 110 111 104 104 105 97 101 91 85 86 85 87 81 79 88
64 68 64 78 87 64 66 62 63 66 75 66 100 128 128 120 124 118 120 120 130 83 82 84 85 95 97 87 94 96 86
62 61 59 58 52 58 64 127 127 118 114 110 110 104 108 88 113 103 89 95 93 84 86 87 81
62 60 63 61 59 62 63 65 72 105 102 101 106 102 97 109 109 115 103 100 101 105 104 105 98 98 95
34 51 65 58 51 75 86 86 88 116 117 116 115 111 115 115 116 71 90 79 76 90 82 96 117 74 103
65 61 65 67 75 68 65 67 68 68 111 109 102 112 88 99 97 98 99 81 108 94 89 93 86 82 85 87 81
54 58 57 57 58 67 69 70 90 140 131 130 128 136 137 137 140 112 131 121 86 97 90 96 96 100 95
73 72 66 61 60 68 73 57 59 56 64 55 79 181 170 178 171 172 165 162 186 85 158 114 85 84 82 100 78 85 94
62 78 69 66 61 62 67 61 50 50 50 63 83 153 152 142 143 137 138 141 156 136 152 130 111 122 96 91 93 89 92
59 57 60 58 57 53 56 59 59 57 56 86 120 112 110 94 96 94 94 108 79 90 62 80 70 69 79 70 76 78
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58 58 57 58 57 60 60 58 58 58 58 80 126 126 98 93 91 94 100 100 72 95 79 78 79 83 77 76 86 97
54 59 65 62 57 61 57 57 53 62 66 124 124 120 114 112 112 111 111 97 100 98 98 94 88 90 100 98 93
57 69 55 67 62 68 60 70 68 69 57 60 73 103 100 100 94 100 98 104 97 116 108 93 93 91 90 88 92 92 89
50 58 59 60 60 64 64 65 92 112 100 10 99 98 97 90 95 83 100 85 78 90 87 90 85 79 86
73 80 73 67 66 66 65 69 64 62 61 57 100 114 114 128 118 113 117 130 128 107 98 104 106 124 111 126 125 111 118
57 54 53 53 54 50 53 55 64 53 54 55 79 113 107 104 107 106 111 109 127 138 111 105 89 89 94 90 88 100 79
60 53 53 56 67 67 52 60 60 60 70 72 90 110 103 104 105 107 121 98 102 90 88 77 79 107 111 86 100 98 105
55 57 60 60 57 57 57 58 69 90 95 95 85 84 86 84 94 104 72 63 88 86 83 82 80 77 72
55 62 61 65 64 64 67 90 100 100 90 94 100 96 105 102 96 94 106 100 105 102 90 96 110
59 56 61 59 5 63 59 56 61 62 61 62 74 118 112 114 110 112 111 99 96 95 88 90 90 86 86 90 87 90 90
63 66 66 63 55 49 57 59 58 61 77 115 113 107 105 105 106 111 131 112 116 115 109 100 106 107 99 106 99
59 63 66 62 58 55 50 49 57 53 68 88 102 122 108 94 95 94 95 99 100 112 105 144 138 111 109 93 95 99 97
59 56 77 78 60 80 70 63 79 71 62 59 88 128 124 128 118 124 124 124 123 110 95 89 80 90 88 126 100 88 87
55 58 56 52 56 43 56 55 78 53 63 64 78 166 160 156 156 160 156 156 190 127 94 94 90 94 91 73 86 123 104
70 68 69 65 63 63 57 60 72 137 136 130 127 124 124 110 109 105 94 91 93 94 94 93 93 90 92
69 68 70 78 66 65 66 64 64 66 87 166 148 148 150 144 140 140 100 108 102 114 92 79 83 96 97 80 92
66 60 56 53 53 59 61 58 59 60 71 118 105 96 96 109 107 98 86 96 109 107 98 86 91 90 95 94 99
58 60 60 60 58 60 60 57 58 60 84 120 95 132 99 90 90 88 90 81 81 77 75 69 76 74 76 80 88
60 56 69 66 67 66 66 70 69 66 72 128 127 128 124 120 120 118 118 104 100 108 98 99 100 87 88 88 88
60 64 66 65 65 63 64 65 67 92 127 114 94 99 99 99 105 88 88 74 84 86 85 89 89 89 87 103
57 60 67 61 61 70 67 65 65 65 70 94 167 171 194 164 155 155 160 177 159 92 153 103 95 95 118 111 94 89
68 69 70 70 69 70 73 69 65 65 65 73 113 94 94 99 95 94 110 99 98 95 97 97 95 93 90 89 88 87
68 80 68 68 68 68 68 66 65 65 80 137 130 135 134 135 135 130 125 106 100 120 113 113 102 9 89 97 99
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114 99 80 93 93 102 99 81 89 90 99 95 102 73 79 79 79 73 70 70 62 76 55 55 48 59 44 67 56
85 81 81 80 78 78 77 80 88 88 96 70 63 55 56 52 50 52 52 52 47 47 57 57 57 47 48
95 93 88 96 100 100 99 98 98 98 99 102 107 107 99 78 74 74 74 74 80 80 77 88 65 68 70 58 65 65 63
73 72 92 88 93 78 81 76 80 86 81 80 82 84 108 68 71 78 75 74 74 77 77 82 65 49 70 62 67 60 51
93 94 90 91 95 90 90 90 95 95 90 95 96 97 122 77 80 83 74 73 63 64 64 59 61 53 58 51 55 58 57
101 103 98 98 105 116 111 106 104 104 124 72 75 83 83 70 74 74 84 83 82 78 78 80 80 80 83
97 97 93 100 98 99 96 99 100 98 114 56 61 55 57 58 55 57 64 60 60 58 55 57 58 59 56
79 87 78 81 82 88 92 98 93 86 77 83 90 92 109 82 78 72 71 67 73 73 73 53 75 65 58 58 50 49 40
86 98 98 106 106 103 103 99 99 96 93 108 64 61 63 60 64 62 62 71 49 58 51 50 37 43 38 51
106 105 102 97 99 95 90 116 106 88 112 107 101 99 121 70 70 71 74 70 70 70 78 38 80 56 53 50 45 54 46
83 92 100 95 96 96 86 88 96 96 96 65 65 65 60 58 48 58 65 63 50 60 57 60 60 60 65
78 94 90 85 76 93 77 89 94 88 92 93 93 93 101 59 59 57 48 48 48 50 58 66 51 48 43 42 43 37 40
107 120 108 108 99 96 96 97 95 108 120 56 54 45 51 56 53 53 74 59 57 85 63 75 57 59 55
105 97 97 101 103 106 106 97 104 107 106 107 107 113 123 67 69 68 67 68 69 69 66 55 90 70 63 59 60 59 54
124 109 107 105 100 97 97 90 89 92 90 90 126 89 88 78 83 82 80 78 73 79 105 77 74 66 65 70 73
88 79 80 80 91 80 87 88 80 86 86 86 112 62 57 59 60 60 58 59 60 66 59 56 52 55 58 55 41
92 90 89 90 90 93 94 92 92 92 114 68 71 68 58 56 52 53 57 50 53 49 46 60 47 47 45
109 94 94 90 94 90 90 90 100 103 105 112 126 65 68 72 63 53 62 65 61 77 62 63 53 65 50 54 56
106 91 89 89 91 104 118 86 84 81 88 78 80 90 73 70 67 56 50 53 55 54 56
90 92 96 91 84 96 99 104 111 71 59 64 58 53 59 53 65 68 64 52 49 47 50 51 52
84 83 79 70 76 74 84 97 104 136 97 90 75 74 70 68 68 84 69 50 52 56 51 50 42 47
91 88 96 97 71 88 91 97 92 101 94 87 104 69 61 65 61 60 66 70 74 63 58 66 63 57 54 53 61
88 87 92 92 87 81 93 93 113 75 68 59 58 59 54 55 60 43 50 55 53 49 46 51 44
88 81 86 86 86 84 88 90 122 81 81 74 80 69 68 64 69 50 75 64 52 55 52 50 54
82 85 100 92 100 90 92 92 99 95 108 94 82 82 88 90 87 82 80 80 80 71 68 58 52 52
88 86 92 80 83 83 82 93 90 90 115 74 74 75 60 60 53 53 60 50 65 46 52 52 52 46 49
98 93 98 94 94 94 104 99 118 65 62 61 66 66 60 70 72 66 62 63 46 45 48 64 44
87 90 87 87 106 97 95 98 94 100 91 92 95 96 116 62 58 60 62 60 59 59 57 44 57 44 44 34 42 36 37
94 89 93 101 87 111 124 92 99 90 90 95 96 96 142 88 88 84 83 82 84 89 96 48 46 46 46 45 47 39 42
99 90 93 88 85 83 85 90 90 59 59 72 57 63 51 50 60 37 57 58 40 47 39 40 40
104 104 102 100 106 99 101 103 101 103 110 53 54 53 53 51 54 56 58 75 50 48 51 49 57 49 47
92 81 70 70 88 76 74 100 115 115 120 80 87 80 87 77 88 88 87 48 69 51 43 66 54 63 80
83 85 87 90 82 90 97 90 90 88 93 91 136 70 64 73 60 58 61 61 71 52 78 61 64 59 62 62 57
92 98 90 90 92 100 104 104 104 106 135 80 86 86 84 88 88 88 80 58 86 65 100 52 43 43 46
91 82 113 114 109 98 98 97 105 108 91 93 89 97 117 94 89 87 93 90 87 81 82 38 74 51 33 49 29 52 27
100 100 88 106 100 96 88 89 91 86 73 73 73 90 110 102 95 92 94 90 89 93 113 77 92 77 64 68 62 49 47
76 83 78 84 84 80 76 76 77 81 82 83 80 118 68 64 64 60 60 60 60 62 46 54 59 32 39 32 34 34
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92 88 88 88 90 92 88 89 89 88 88 90 90 113 69 69 56 51 56 59 60 65 47 63 49 54 51 50 54 58
96 94 104 99 92 106 95 95 92 103 99 98 107 51 51 53 54 49 48 50 48 60 42 40 36 37 37 34 42
98 84 87 90 87 90 97 95 100 102 96 88 95 95 99 55 51 57 55 55 64 60 74 68 54 56 57 51 52 34 48
85 88 70 82 89 89 90 90 90 94 121 67 57 59 56 62 63 52 55 47 64 49 50 56 57 52 49
99 96 96 96 97 97 98 98 98 88 92 93 93 94 130 72 73 70 73 69 73 74 72 58 69 67 67 58 59 68 78
80 83 81 79 74 73 74 80 95 75 81 80 80 82 110 69 68 68 59 64 67 78 85 68 63 57 55 53 52 57 53
90 89 89 87 104 79 99 95 100 98 98 98 102 102 118 69 64 63 65 68 70 59 67 67 60 69 59 55 47 49 38
72 77 77 79 80 80 80 88 88 88 100 55 50 56 52 56 50 57 54 66 34 38 47 48 44 40 40
100 106 96 100 100 110 108 108 110 70 45 45 40 42 46 40 40 40 33 36 45 36 40 38 40
88 88 95 86 88 88 89 90 90 88 90 90 90 88 102 72 70 59 60 60 62 68 60 52 53 50 45 48 48 44 53
100 99 99 85 105 87 90 100 100 96 98 98 126 57 48 49 51 49 50 56 55 57 55 51 46 51 49 42 46
102 107 107 96 97 90 100 95 84 82 77 93 99 102 148 90 62 55 55 57 58 66 56 77 61 99 95 64 63 54 51
91 84 82 81 100 100 81 86 86 100 100 97 93 80 117 74 74 76 70 75 74 74 72 86 71 45 61 51 65 59 53
78 84 99 84 92 84 93 100 83 85 82 95 94 95 124 86 86 83 84 85 86 86 104 77 70 56 52 56 53 55 56
103 100 86 95 90 90 90 93 93 96 98 83 80 82 77 78 78 70 63 74 70 72 57 65 60 60 37
96 104 104 102 106 106 110 112 100 104 108 108 118 83 90 87 80 80 79 79 80 60 60 60 75 57 47 49 57
86 90 96 92 86 89 97 99 95 93 96 96 112 52 47 44 46 59 47 40 37 44 46 59 47 40 37 37 43
90 88 88 88 88 80 86 85 88 88 90 90 105 80 93 67 70 70 69 63 64 61 58 57 52 50 50 53 57
89 90 90 96 96 95 95 95 90 90 90 100 122 67 67 65 66 68 67 67 67 56 56 55 47 47 48 50 50
88 88 88 88 89 96 96 96 90 97 97 122 77 78 74 56 60 60 60 65 59 59 59 48 50 50 54 50
90 100 92 94 94 87 85 90 99 98 90 99 105 170 82 84 95 89 80 78 78 80 88 65 73 55 65 55 65 63
86 90 94 94 96 97 98 99 97 99 99 98 97 105 66 56 56 56 57 58 65 56 53 52 54 57 51 49 48 49
99 99 100 107 102 102 98 99 90 98 98 98 98 123 98 97 94 98 96 96 98 70 70 59 50 57 57 57 58 68
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64 66 56 58 50 56 56 58 58 58 60 60 60 60 61 84 80 78 71 71 68 66 68 70 70 70 61 60 66 66
49 50 54 54 55 55 56 44 47 48 50 56 58 92 92 89 84 84 84 70 71 65 65 65 66 66 65 66
58 62 56 54 65 64 64 60 60 60 62 57 58 60 60 60 56 86 85 85 88 90 88 88 80 90 110 98 88 88 102 98
59 59 49 49 68 60 63 55 57 56 57 46 56 56 56 56 76 98 98 96 98 88 88 97 97 94 94 90 76 76 92 73
56 58 59 62 57 58 56 56 57 58 60 60 60 58 55 57 76 81 78 72 71 68 70 83 80 80 83 80 67 67 63 57
91 82 71 55 56 57 57 60 57 63 56 54 73 88 86 92 83 84 83 84 94 99 94 88 83 79 81 82
57 57 57 56 56 55 55 54 58 59 59 59 70 80 70 69 69 70 67 70 82 62 67 72 71 63 62 58
63 57 47 59 51 58 49 47 56 46 50 59 55 61 53 54 75 103 104 112 116 105 103 102 113 100 103 94 91 88 88 81
47 54 46 37 54 38 43 49 49 52 44 41 41 58 88 70 75 72 80 92 92 93 72 90 79 73 69 61 60
42 46 54 52 56 59 50 45 48 74 54 45 60 56 49 49 89 71 71 68 69 62 62 63 61 57 70 61 64 62 62 64
46 43 48 46 64 74 65 61 57 65 65 65 65 63 63 61 60 60 60 61 63 72 70 81 92 90 85 85
32 34 49 38 38 38 46 40 46 47 48 48 49 46 46 48 50 59 59 59 53 54 54 54 56 54 69 60 58 59 61 56
54 59 59 76 54 52 54 54 50 56 54 60 76 57 60 58 58 57 55 54 61 68 99 70 62 61 58 58
55 56 51 51 55 53 55 53 56 53 59 59 59 58 56 59 81 79 84 70 77 77 80 80 88 84 90 79 80 74 71 70
74 79 70 66 67 64 62 61 59 59 58 56 61 78 74 74 73 74 79 75 75 77 77 80 82 112 86 82 76
41 43 43 44 44 45 53 53 53 50 50 55 55 55 70 64 64 64 65 60 68 60 68 91 91 8 88 76 70 70
45 50 50 48 48 50 50 48 52 51 51 52 77 64 66 58 57 55 54 54 58 58 58 60 67 58 55 70
56 106 52 64 71 71 70 70 76 73 73 73 72 74 75 91 89 90 84 80 82 107 89 102 98 98 88 84 80 80
54 55 66 51 53 52 51 63 67 120 120 130 107 107 112 104 90 99 101 105 102 107 200 99
53 55 57 54 51 50 50 50 56 56 70 68 65 65 65 59 59 58 90 96 96 96 64 66 66 66
47 48 53 62 48 45 47 46 51 63 70 86 83 74 68 68 66 66 65 72 73 68 73 73 72 75 75
59 45 63 58 56 40 49 72 41 57 51 61 55 44 63 71 69 70 70 70 74 79 84 89 99 99 89 85 84 80
43 51 51 49 44 45 42 44 44 44 74 77 70 68 68 67 65 65 76 75 80 90 90 87 85 80
57 53 60 56 58 58 58 56 60 59 78 87 88 78 82 78 72 72 81 69 78 77 69 72 68 68
50 60 55 49 55 59 53 62 51 51 60 60 79 92 93 93 90 92 92 93 90 113 104 88 82 90 93 94
49 56 47 47 51 50 45 46 48 54 56 56 75 64 64 61 62 64 65 65 64 94 64 89 64 65 57 59
47 40 39 40 40 50 50 50 44 46 76 72 70 72 88 87 80 89 110 96 97 99 102 101 94 90
37 37 33 40 44 39 37 59 50 43 44 49 49 41 40 43 74 66 65 67 67 70 69 69 72 71 84 85 85 74 85 74
48 43 42 3 46 53 48 59 67 47 49 43 45 49 61 48 80 92 91 90 89 89 89 89 98 96 90 88 85 79 79 77
40 52 45 44 44 37 43 32 40 45 52 86 86 85 78 80 85 80 85 83 89 89 80 90 86 70
48 49 43 52 50 48 51 48 46 50 51 53 64 55 58 57 55 54 57 60 90 83 70 66 65 68 66 67
47 68 59 55 28 44 58 54 43 67 77 77 78 85 82 79 80 80 82 80 85 85 93 89 75 70 73 80
56 61 58 59 58 52 60 59 68 62 57 62 59 60 83 103 89 86 73 80 77 77 78 92 92 90 84 90 82 81 78
43 48 60 47 43 48 46 46 48 62 68 68 88 99 89 89 88 90 90 90 89 110 109 106 99 111 101 105
33 49 36 30 57 53 52 48 40 41 50 54 38 40 37 46 59 97 96 96 96 92 90 93 78 78 85 77 61 71 70 52
43 41 52 52 45 60 52 48 44 44 51 44 34 45 45 44 68 74 79 70 68 70 71 72 73 73 106 75 69 68 66 63
39 34 38 38 37 42 42 44 42 42 42 36 40 41 44 74 80 74 73 73 70 69 69 80 84 83 88 80 94 83 84
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67 58 58 58 58 55 56 58 58 60 58 56 55 58 55 79 95 95 79 78 79 77 82 84 80 81 73 68 67 67 67
33 35 40 43 39 40 43 39 32 40 43 37 37 37 52 120 120 116 112 110 110 110 109 109 109 110 110 111 105 98
49 55 49 51 47 63 43 57 57 58 47 60 58 57 51 62 64 84 80 83 80 84 86 81 100 85 84 88 85 84 86 89
48 57 55 53 44 50 50 50 54 54 55 57 82 62 62 56 56 55 52 52 60 56 55 65 57 59 59 51
58 73 68 53 62 48 49 48 47 47 50 46 45 38 41 42 88 62 65 68 74 65 69 67 90 70 84 58 71 57 59 55
46 49 49 49 47 47 47 41 47 47 54 46 54 45 46 50 64 66 59 66 60 60 67 63 65 86 90 86 75 65 65 61
51 43 43 46 58 48 50 50 56 56 55 66 67 66 66 68 79 65 66 67 67 68 76 78 70 70 75 75 73 66 70 57
33 49 50 50 56 48 48 47 48 46 46 46 56 61 55 63 58 56 59 66 66 73 63 77 66 70 64 65
33 45 45 45 36 40 40 40 42 42 46 100 110 92 90 100 108 110 110 112 114 106 110 102 106 100
42 42 42 44 45 51 40 48 44 48 48 48 48 50 50 50 57 77 73 70 66 68 70 70 90 86 86 80 73 83 80 80
48 46 30 44 46 54 42 36 28 35 38 38 44 45 52 76 66 67 72 69 70 76 70 88 86 75 73 74 73 70
50 43 58 76 51 47 51 60 51 45 48 40 42 44 38 57 88 84 76 74 75 76 74 75 75 79 83 83 102 94 89 86
59 58 49 50 47 69 69 55 73 66 58 71 62 53 53 48 86 80 82 80 80 82 81 80 73 62 59 67 66 68 73 64
67 48 47 53 43 47 34 47 44 47 59 59 44 44 47 50 67 72 72 72 69 66 69 66 68 72 63 52 60 53 60 70
57 57 53 59 70 67 61 58 56 57 42 47 70 84 88 80 78 78 77 78 84 90 90 81 73 86 84 84
50 46 55 51 58 59 61 69 70 67 67 67 66 56 77 80 70 69 68 68 68 70 70 85 77 85 75 72 70 64
41 36 39 42 43 38 33 34 39 41 39 40 42 42 78 64 80 75 89 67 73 75 69 75 89 67 73 75 69 65
52 57 57 55 55 55 55 53 55 55 55 55 55 50 78 69 70 88 69 68 68 68 68 64 64 64 63 62 60 63
50 50 58 55 56 57 38 44 44 44 46 48 50 50 65 84 84 80 84 82 85 85 90 90 90 94 100 87 88 88
55 57 57 56 63 59 53 52 52 60 62 62 60 82 85 72 70 78 77 77 88 70 73 86 89 78 78 78 78
47 54 63 53 50 45 48 58 53 55 62 53 54 55 56 84 88 86 80 75 73 72 74 74 75 67 74 73 71 73 76
51 48 52 53 53 52 57 57 55 62 54 59 59 57 56 61 81 81 78 78 77 70 87 75 70 70 73 75 76 73 72
66 65 59 53 80 64 56 56 56 60 61 60 57 56 57 70 72 70 70 63 62 63 62 61 61 72 71 70 70 70 68
S.
N
O
.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
4
0
M
I
N
4
5
M
I
N
5
0
M
I
N
5
5
M
I
N
6
0
M
I
N
6
5
M
I
N
7
0
M
I
N
7
5
M
I
N
8
0
M
I
N
8
5
M
I
N
9
0
M
I
N
9
5
M
I
N
1
0
0
M
I
N
1
0
5
M
I
N
1
1
0
M
I
N
1
1
5
M
I
N
1
2
0
M
I
N
E
X
T
U
B
M
A
C
-
I
n
d
5
M
I
N
1
0
M
I
N
1
5
M
I
N
2
0
M
I
N
2
5
M
I
N
3
0
M
I
N
3
5
M
I
N
66 66 69 70 72 72 69 70 74 73 73 74 74 74 74 74 86 0.85 0.85 0.9 0.95 1 1 1 1
66 66 66 66 69 66 62 65 67 67 61 66 76 76 80 0.95 1 1 1 1 1 1 1
98 97 93 90 87 87 78 78 76 75 72 74 74 75 78 78 74 78 0.85 0.85 0.9 1 1 1 1 1
73 73 64 64 64 64 73 70 70 70 72 72 70 72 72 72 72 84 0.9 0.9 0.9 1 1 1 1.1 1.1
57 57 58 60 77 77 67 67 81 75 64 62 61 62 66 66 68 74 0.9 1 1 1 1 1 1 1
79 72 75 77 80 78 70 74 69 69 77 77 78 90 0.95 1.7 1.1 1.1 1.1 0.9 1 1
63 63 63 62 70 68 66 66 66 66 65 68 68 90 0.9 1 1 1 1.2 1.2 1 1
80 85 86 86 85 88 90 90 90 98 98 105 102 102 102 102 106 90 0.9 0.95 1 1 1.1 1.1 1.1 1.1
64 59 62 68 65 69 65 68 68 70 63 61 61 61 76 0.8 0.9 1 1 1 1 1 1
67 66 67 68 70 70 73 70 68 68 70 74 75 71 71 75 75 84 0.8 1 1 1.05 1.1 1.1 1.2 1.1
80 80 78 89 92 86 89 83 88 88 89 92 92 74 0.9 0.9 0.9 0.9 1 1 1 1
56 56 58 57 58 58 60 61 61 62 65 66 60 60 59 58 59 69 0.9 1 1 1 1 1 1 1
57 57 57 57 57 58 58 58 58 60 56 58 66 82 1.2 1.1 1 1 1 1 1 1
70 70 73 70 70 70 70 73 75 70 70 70 70 70 75 75 75 75 1 1 1 1 1 1 0.9 1
99 100 97 96 90 98 90 88 86 82 80 83 80 80 80 83 0.9 0.9 0.9 0.9 1.1 1 1 1
70 68 70 70 69 70 74 70 70 69 70 69 68 79 80 78 0.9 1 1 1 1 1 1.2 1.2
64 64 64 59 60 60 60 60 60 62 64 60 62 65 1 1 1 1 1 1 1 1
88 80 100 68 78 70 64 70 68 68 69 68 70 70 70 90 1.2 1.2 1.15 1.15 1.15 1.15 1.2 1.2
99 92 94 99 92 102 92 98 98 100 0.9 1 1.1 1 1 1 1 1
69 69 68 69 60 70 70 72 72 72 74 88 1.05 1 1 1 1 1 1 1
75 73 77 85 73 71 73 74 74 74 89 91 108 0.9 0.8 0.8 0.8 0.8 0.9 0.8 0.8
77 72 70 64 65 63 68 67 56 57 63 67 66 70 72 72 0.9 1 1 1 1 1 1 1
88 82 78 90 87 87 85 83 82 94 94 100 0.9 1 1 1 1 1 1 1
70 73 71 73 74 77 77 77 75 78 80 80 0.8 0.9 1 1 1 1.1 1 1
90 89 93 90 87 86 85 85 84 84 88 90 90 94 1 1 1 1.1 1.2 1.2 1.3 1.3
60 61 62 57 60 57 58 59 59 59 59 58 61 80 0.95 0.8 0.8 0.8 0.9 0.9 1 1
89 89 89 84 85 84 84 83 87 84 84 114 0.9 1 1 1 1 1.1 1.2 1.2
72 70 74 75 75 69 70 78 77 78 78 78 78 83 80 81 81 101 0.9 1 1.1 1 1.1 1.2 1.1 1
77 80 80 80 83 83 87 87 86 77 77 77 78 78 79 80 80 87 0.9 1.1 1.1 1 1 1 1.2 1.2
69 79 75 78 76 76 74 70 69 70 70 70 72 0.9 1 1 1 1 0.9 0.8 0.9
62 61 62 62 60 62 65 64 63 67 67 66 66 68 0.9 1.2 1.2 1.2 1.3 1.2 1.2 1.2
82 74 74 70 67 63 68 70 68 688 76 80 80 88 1.2 1.1 1.1 1.05 0.75 0.8 0.9 0.9
81 81 80 78 81 83 81 87 108 87 88 86 85 84 85 84 114 1 1 1 0.9 1 1 1 1
101 99 102 99 96 96 95 95 96 108 114 114 114 104 1.2 1 1.1 1.2 1 1 1 1-Jan
58 55 70 69 67 75 74 68 67 68 71 71 69 68 68 69 69 83 1 1 1 1.2 1.1 1.1 1.2 1.2
62 64 66 72 62 65 76 69 70 68 68 72 62 64 66 72 75 76 1.2 1 1 1 1 1 1 1.1
80 82 78 78 84 83 80 80 80 81 82 80 80 83 84 82 80 1 1.1 1 1 1 1 1 0.8
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72 70 68 68 71 69 64 64 66 67 67 68 68 70 68 68 79 0.9 1 1 1 1 0.9 1 1
94 109 112 107 100 98 100 105 103 118 118 120 112 112 120 124 0.9 0.9 1 1 1 1 1.1 1
82 89 82 80 78 76 81 76 81 84 83 83 88 87 89 85 81 85 1 1 1 1.1 1.1 1.1 1.1 1
51 57 62 60 56 58 57 58 60 60 60 59 60 81 1 1 1 1 1 1 1 1
60 87 55 58 61 62 64 65 62 64 64 68 62 66 70 64 66 88 1 1 1 1 1.2 1.2 1.2 1.2
77 63 64 64 64 64 60 60 65 65 63 66 67 68 68 68 70 83 1 1 1 1.2 1.1 1 1 1
70 70 73 67 67 69 69 70 68 90 69 69 64 70 69 68 69 81 1 1 1.2 1.2 1.2 1.1 1.1
60 60 60 63 62 77 77 77 69 68 68 70 70 70 1 1 0.9 0.9 0.9 0.9 0.9 0.8
100 108 102 102 102 100 100 101 100 106 106 110 1 1 1 0.9 0.9 0.8 0.8 0.8
76 78 70 78 83 86 78 83 86 86 97 97 86 94 90 92 93 88 1 1 1 0.9 0.9 0.9 0.9 0.9
76 87 70 71 73 73 75 79 72 77 83 81 83 84 79 88 1 1 1 1 1 1 1 1.2
93 75 76 74 79 77 71 72 75 75 73 75 70 70 71 75 75 104 1 1 1 1 1 1.2 1.2 1.2
60 60 58 59 55 61 62 60 56 60 56 61 57 56 58 66 63 88 0.8 0.9 0.9 0.9 0.7 0.8 0.9 0.9
73 73 77 79 80 82 79 79 80 81 79 77 75 73 74 73 77 90 1 1 1 1.2 1.3 1.2 1.2 1
73 70 68 66 67 70 70 61 67 68 67 68 68 74 1 1 1 1 1 0.9 0.9 0.9
65 58 62 622 62 62 64 61 60 63 68 68 68 68 68 68 1 1 1 1 1 1 1 1
61 63 67 66 72 61 79 70 67 66 63 71 70 74 76 80 1 1 1 1 1 1 1 1
60 60 60 62 63 64 64 64 64 64 64 64 66 62 65 66 1 1 1 1 1.2 1.2 1.2 1.1
88 90 90 90 67 60 68 74 74 74 75 75 75 77 78 78 1 1 1 1 1.2 1.2 1.2 1.1
78 77 77 74 73 722 70 71 75 78 75 75 75 74 71 1 1 1 1 1 1 0.9 0.9
74 73 74 65 68 67 68 65 67 60 60 76 7 76 76 76 100 1 1 1 1 1 1 1 1
72 72 73 76 78 78 80 82 83 85 85 88 85 85 85 80 84 1 1 1 1 1 1 1 1
63 67 68 70 70 74 73 72 72 70 70 70 70 70 70 70 73 1 1 1 1.2 1.2 1.1 1.2 1
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1 1 1 1 1 1 1 1 1 1 1 1 0.9 0.9 160 0 4 0 140 40 0 B 0
1 1 1 1.05 1 1 0.9 5 0 4 0 100 0 0 A YES
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 280 3 2 6.5 200 120 0 C 0
1.1 1.1 1 1 1 1 1 1 1.1 1.1 1 1 1 1 1 1 1 580 1 4 0 180 80 0 B YES
1 1 1 0.9 1 1 1 1 1.2 1.2 1 1 1 1 0.9 0.9 0.9 740 0 4 0 240 140 0 B YES
1 1 1 1 1.2 1.2 1.2 1.2 1.3 1.3 1.2 1.2 1.3 320 0 4 5 360 200 0 C 0
1 1 1 1 1 1 1 1 1 1 1 1 1 40 0 4 0 140 40 0 B 0
1 0.8 0.85 1 1 1 1 1 1.1 1.1 1 1 1.1 1.1 1.1 1.1 1 500 0 4 0 140 40 0 C YES
1 1 1 1 1 1 1 1 1 1 1 1 1 1 65 0 3 0 160 60 0 A 0
1.1 1.2 1.2 1.3 1.3 1.2 1.3 1.15 1.3 1.3 1.2 1.2 1.2 1.3 1.4 1.4 1.3 300 1 3 1.5 240 140 0 B 0
1 1 1 1 1 1 1 1 1.1 1.1 1.2 1.1 1 200 0 4 0.5 160 100 30 B 0
1 1 1 1 1 0.9 0.9 1 1 1 1 1 1 1 1 1 1 200 0 3 0 140 40 0 A YES
1 1 1 1 1 1 1 1 1 1 1 1 0.9 70 0 4 2 300 200 0 B 0
1 1.25 1.12 1.2 1.2 1.2 1 1 1 1 1 1 1 1 1 1 100 0 3 1 230 130 0 A 0
1.2 1 1 1 1 1.2 1 1 1 1 1 1 1 1 1 230 0 3 4 240 140 50 C 0
1.1 1.1 1 1 1 1 1 1 1 1 1.1 1 1 1 1 66 0 4 1 200 100 30 B YES
1 1 1 1 1 0.9 0.9 1 1 1 1 1 0.95 70 0 4 0 170 70 0 B 0
1.2 1 1 1 1 1 1.1 1 1 1 1 1 1 1 1 75 2 4 3 240 140 0 C 0
1.2 1 1 1 1 1 1 1 1 180 0 3 2 200 100 0 B 0
1 1 1 1 0 1 1 1 1 1 1 50 0 4 0 120 0 0 B 0
0.8 0.7 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 0.8 65 2 3 0 140 40 0 B 0
1.2 1 1 1 1 1.1 1.1 1 1 1 1 1 1 1 1 510 0 4 4.5 240 120 0 C YES
1.1 1 1 1 1 1 1 1 1 1 1 50 2 4 0 140 40 0 B YES
1 0.9 1 1 1 1.1 1 1 1 1 1 62 0 4 0 100 0 0 A 0
1.1 1 1 1 1 1 1 1 1 1 1 1 1 480 5 2 3 250 150 70 C 0
1 1 0.8 0.8 0.9 0.8 0.9 0.8 0.9 0.9 0.9 0.9 0.8 20 0 4 0 100 0 0 A 0
1.1 1 1 1 1 1 1 1 1 1 1 20 0 3 0 200 100 0 A 0
1 1 1 1 1.1 1 1 1 1 1 1 1 1 1 1 1 1 200 2 3 4 240 140 0 B 0
1.1 1 1 0.9 1 1 1.11 1 1 1 1 1 1 1 1 1 1 120 2 4 2 160 80 0 B 0
0.9 0.9 0.9 0.9 0.9 0.8 0.8 0.8 0.8 0.8 0.8 40 0 3 0 130 0 0 A 0
1.2 1.1 1 1 1 1 1 1 1.1 1 1 1 1 40 0 2 2 240 140 0 B 0
0.9 1.1 1.15 1.2 1.05 0.9 0.9 0.9 0.9 1 1 1 1 180 0 4 4 220 120 0 B YES
1 1 1 1 1.15 0.9 1.1 1 1 1 1 1 1 1 1 1 60 1 4 0 130 0 0 B 0
1.2 1 1 1 1 1 1 1 1 1 1 1 1 20 2 3 3 200 100 0 B 0
1.2 1.1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 140 1 3 4 220 120 150 C YES
1.2 1.1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1000 0 3 3 320 200 0 C YES
0.8 0.9 0.9 1 1 1 1 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 0.9 40 0 2 0 100 0 0 A 0
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0.9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 60 0 4 0 140 0 0 B 0
0.9 0.9 0.9 1 1 1 1 1 1 1 1 1 1 1 1 250 0 3 0 160 100 0 C YES
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 650 0 3 2 200 125 0 B 0
1.1 1 1 1 1 1 1 1 1 1 1 1 1 150 0 4 0 120 0 0 B 0
1.1 1.1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 100 0 4 3 240 140 0 B 0
1 1 1 1.1 1.1 1 1 1 1 1 1 1 1 1 1 1 1 210 0 3 2 200 100 0 B YES
1.1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 40 0 4 0 200 100 0 B YES
0.8 0.8 0.8 1 1 1 1 1 1 1 1 1 1 50 2 4 0 100 0 0 A YES
0.8 0.9 0.9 0.9 0.9 0.9 0.9 0.91 1 1 10 3 4 0 100 0 0 A YES
0.9 0.8 0.8 0.8 1 1 1 1 1 1 1 1 0.9 0.9 0.9 0.9 0.9 300 2 3 0 100 0 0 B 0
1.2 1.2 1.2 1.1 1.1 1 1 1 1 1 1.1 1.1 1 1 1 200 0 4 0 180 60 0 C YES
1.1 1.1 1.1 1 1 1 1 1 1 1 1 1 1 1 1 1 0.9 150 0 3 0 260 140 0 C YES
0.9 1 1 1 0.9 0.85 0.9 0.9 0.8 0.8 0.9 0.9 0.9 0.9 0.9 0.9 0.85 180 3 3 0 200 100 0 C 0
1 1 1 1 1 1 1.1 1.1 1 1 1 1 1 1 1 1 1 90 0 3 0 200 100 0 B YES
0.9 1 1 1 1 1 1 1 1 1 1 1 1 220 0 4 0 160 0 0 A 0
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 15 0 3 0 200 100 0 B 0
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 30 0 4 0 100 0 0 A 0
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 15 0 3 2 200 100 0 B 0
1.1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 200 0 3 3 200 100 40 B 0
1 1 1 1 1 1 1 1 1 1 1 1 1 1 10 0 4 0 100 0 0 A 0
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 40 0 4 0 100 0 0 B 0
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 320 0 2 0 250 150 0 C 0
1 1 1 1 1 1 1.2 1.2 1.3 1.3 1 1 1 1 1 1 240 2 2 2 320 200 0 B 0
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